LOD, Israel--(BUSINESS WIRE)--TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal ...

Eli Lilly (NYSE: LLY) has entered into a licensing and development agreement with TransPharma Medical Ltd., an Israel-based developer of trans-dermal drug delivery solutions. The deal relates to a ...

LOD, Israel--(BUSINESS WIRE)-- TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal ...

LOD, Israel--(BUSINESS WIRE)--TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal ...

Eli Lilly and Co. will pay $35 million for rights to an osteoporosis medicine delivered through the skin, the Indianapolis drugmaker announced today. Lilly has signed a licensing and development ...

Syneron Medical ($ELOS) creates cosmetic lasers and other devices to help improve people's looks, focusing on processes like body contouring, hair removal, acne and ...

TransPharma Medical, a Lod, Israel-based company developing transdermal drug delivery technology, has completed a Phase Ia trial of its ViaDerm-GLP1 agonist being developed to treat Type 2 diabetes.

TransPharma Medical Ltd. said it will receive an up-front payment of $35 million as part of a deal with Eli Lilly & Co. to develop TransPharma's needle-free ViaDerm-PTH (1-34) for osteoporosis. Under ...

Transpharma International (part of the Walden Group) – the pharmaceutical freight and logistics specialist – has entered into a strategic agreement with Arra Group, a Polish logistics company and key ...

TransPharma Medical Ltd. has announced the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis. In June 2008, Eli Lilly ...